Race-based therapeutics.
作者： Clyde W. Yancy
DOI: 10.1007/S11906-008-0052-8
关键词: Special populations 、 Medicine 、 Guideline 、 Gerontology 、 Natural history 、 Ethnic group 、 Disease 、 Race and health 、 Race (biology) 、 African american population
摘要: The issue of race in medicine is problematic. Race not a physiologic grouping, and all persons given do necessarily share the same clinical phenotype or genetic substrate. Despite clear signals that certain risk factors diseases vary as function race, translating those differences into race-based therapeutics has been awkward done little to change natural history cardiovascular disease it affects special populations. Among varied populations, African American population appears have most significant adverse variances for well worrisome drug responsiveness varies. Recent guideline statements now acknowledged treatment options are appropriate Americans with disease, especially hypertension heart failure. As more markers become available, need racial designations may lessen, therapies can be optimized patients without regard ethnicity.
springer.com
sci-hub.se 参考文章(59)
UK Prospective Diabetes Study Group, None, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ. ,vol. 317, pp. 703- 713 ,(1998)
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) The Lancet. ,vol. 353, pp. 2001- 2007 ,(1999) , 10.1016/S0140-6736(99)04440-2
Paul G. Shekelle, Michael W. Rich, Sally C. Morton, Col.Sid W. Atkinson, Wenli Tu, Margaret Maglione, Shannon Rhodes, Michael Barrett, Gregg C. Fonarow, Barry Greenberg, Paul A. Heidenreich, Tom Knabel, Marvin A. Konstam, Anthony Steimle, Lynne Warner Stevenson, Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials☆ Journal of the American College of Cardiology. ,vol. 41, pp. 1529- 1538 ,(2003) , 10.1016/S0735-1097(03)00262-6
Sharon Ann Hunt, None, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology. ,vol. 46, pp. 1116- 1143 ,(2005) , 10.1016/J.JACC.2005.08.022
A Hjalmarson, Prevention of sudden cardiac death with beta blockers. Clinical Cardiology. ,vol. 22, ,(1999)
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The New England Journal of Medicine. ,vol. 342, pp. 145- 153 ,(2000) , 10.1056/NEJM200001203420301
Kai C. Wollert, Helmut Drexler, Regulation of Cardiac Remodeling by Nitric Oxide: Focus on Cardiac Myocyte Hypertrophy and Apoptosis Heart Failure Reviews. ,vol. 7, pp. 317- 325 ,(2002) , 10.1023/A:1020706316429
David R. Williams, Toni D. Rucker, Understanding and addressing racial disparities in health care. Health Care Financing Review. ,vol. 21, pp. 75- 90 ,(2000)
V. DeQuattro, J. M. Neutel, V. Papademetriou, M. R. Weir, W. D. Hall, L. M. Prisant, K. Ferdinand, Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. Journal of The National Medical Association. ,vol. 91, pp. 40- 48 ,(1999)
M. Suthanthiran, Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 97, pp. 3479- 3484 ,(2000) , 10.1073/PNAS.050420897